.jpg){kind=small}
Perspective Therapeutics
Manufacturing · Washington, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2401 Elliott Ave Ste 320, Seattle, Washi...Phone Number
(206) 676-0900Revenue
-Stock Symbol
CATXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
4
1
1
1
1
About Perspective Therapeutics
Perspective Therapeutics is a clinical-stage radiopharmaceutical company focused on developing targeted cancer therapies that combine imaging and treatment through a theranostic approach, using proprietary technologies to deliver alpha-particle radiation directly to tumor cells while minimizing damage to healthy tissue, and advancing innovative, image-guided solutions to improve precision, patient selection, and overall treatment outcomes in oncology.Explore more
Perspective Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Perspective Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Perspective Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Perspective Therapeutics is spiking on competitors!
Earning: See what the market has to say on Perspective Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Perspective Therapeutics
Click to see if Perspective Therapeutics had a recent Job posting/layoffs
Check if Perspective Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Perspective Therapeutics has new funding data
Product Launch: Get notified when Perspective Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined Perspective Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Perspective Therapeutics
Compare insights from companies similar to Perspective Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Perspective Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Perspective Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Perspective Therapeutics.
Perspective Therapeutics financials insights
Gather financial insights about Perspective Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$18M
2021
Grant
$5M
Perspective Therapeutics Tech Stack
A closer look at the technologies used by Perspective Therapeutics
Most Recent Scoops
Open Position
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Perspective Therapeutics News & Media
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updates on all three of its advancing clinical programs, [²¹²Pb]VMT-α-NET, [²¹²Pb]VMT01, and [²¹²Pb]PSV359, will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 29 to June 2, 2026 in ChPerspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the first patients were dosed with [212Pb]VMT-α-NET and [212Pb]PSV359 in two new cohorts of Phase 1/2a studies in neuroendocrine tumors and solid tumors, respectively.Perspective Therapeutics, Inc. (CATX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Perspective Therapeutics, Inc. (CATX) Bank of America Global Healthcare Conference 2026 May 13, 2026 5:20 PM EDTCompany ParticipantsJoel Sendek - CFO &...Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
SEATTLE, May 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended March 31, 2026.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Perspective Therapeutics
Sign Up For FreeTo access detailed company insights
Perspective Therapeutics is a clinical-stage radiopharmaceutical company focused on developing targeted cancer therapies that combine imaging and treatment through a theranostic approach, using proprietary technologies to deliver alpha-particle radiation directly to tumor cells while minimizing damage to healthy tissue, and advancing innovative, im... Read More
